All In Biotech

Drug Trial Radar · NCT00829166

A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy

Last checked: Nov 20, 2026Latest source record: Oct 31, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 991 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

991

Actual

Start

Feb 2009

Primary completion

Jul 2012

Study completion Sep 2015

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 26, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib in participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), unmanageable toxicity, or study termination. Once disease progression is reported, all participants will be followed for survival every 3 months until death, loss to follow-up, withdrawal of consent, or study termination.

Conditions

  • Breast Cancer

Interventions

  • Trastuzumab emtansineDrug

    Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.

  • LapatinibDrug

    Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.

  • CapecitabineDrug

    Capecitabine 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)Time frame: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
  2. Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint)Time frame: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
  3. Percentage of Participants Who Died: Second Interim AnalysisTime frame: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
  4. Overall Survival: Second Interim Analysis (Co-primary Endpoint)Time frame: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
  5. Percentage of Participants Who Died: Final AnalysisTime frame: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
  6. Overall Survival: Final AnalysisTime frame: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
  7. Percentage of Participants Who Were Alive at Year 1Time frame: Year 1
  8. Percentage of Participants Who Were Alive at Year 2Time frame: Year 2

Locations

323 sites in 27 countries. Site status is shown where the registry gives one.

  • Site not named

    Chandler, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Anaheim, California

  • Site not named

    Anaheim, California

  • Site not named

    Bakersfield, California

  • Site not named

    Baldwin Park, California

  • Site not named

    Bellflower, California

  • Site not named

    Duarte, California

  • Site not named

    Fontana, California

  • Site not named

    Hayward, California

  • Site not named

    Irvine, California

  • Site not named

    La Jolla, California

  • Site not named

    La Mesa, California

  • Site not named

    Loma Linda, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Montebello, California

  • Site not named

    Newport Beach, California

  • Site not named

    Oakland, California

  • Site not named

    Panorama City, California

  • Site not named

    Riverside, California

  • Site not named

    Roseville, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    San Jose, California

  • Site not named

    Santa Clara, California

  • Site not named

    Santa Maria, California

  • Site not named

    Santa Monica, California

  • Site not named

    South San Francisco, California

  • Site not named

    Thousand Oaks, California

  • Site not named

    Vallejo, California

  • Site not named

    Walnut Creek, California

  • Site not named

    Woodland Hills, California

  • Site not named

    Fort Collins, Colorado

  • Site not named

    Norwalk, Connecticut

Showing 40 of 323 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.